Core Insights - The medical services sector experienced a significant increase of 4.77% on January 5, with Sanbo Brain Science leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Medical Services Sector Performance - Sanbo Brain Science (301293) closed at 70.78, with a rise of 20.01% and a trading volume of 106,700 shares, amounting to a transaction value of 755 million [1] - Likang Life (300143) saw a closing price of 11.38, increasing by 15.18% with a trading volume of 473,200 shares, totaling 518 million [1] - Chengdu Xian Dao (688222) closed at 26.14, up 11.47%, with a trading volume of 277,100 shares, resulting in a transaction value of 704 million [1] - Other notable performers include She Nei Medical (301060) at 10.20 (+10.27%), International Medical (000516) at 4.72 (+10.02%), and Zhaoyan New Drug (603127) at 38.51 (+10.00%) [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.028 billion from institutional investors, while retail investors contributed a net inflow of 174 million [2] - Notable net inflows from institutional investors include Zhaoyan New Drug (603127) with 235 million and Sanbo Brain Science (301293) with 214 million [3] - Conversely, retail investors showed significant outflows from several stocks, including Sanbo Brain Science (301293) with a net outflow of 136 million and Likang Life (300143) with 27.9 million [3]

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing up 0.03% at 26,347.24 points and a total trading volume of HKD 283.46 billion [1] - The Hang Seng Tech Index rose by 0.09%, while the Hang Seng China Enterprises Index fell by 0.22% [1] Blue-Chip Stocks Performance - Kuaishou-W (01024) led blue-chip stocks, surging 11.09% to HKD 73.6, contributing 35.65 points to the Hang Seng Index [2] - Other notable performers included Innovent Biologics (01801) up 6.09% and Chow Tai Fook (01929) up 5.13% [2] - Conversely, China National Petroleum (00857) and Wharf Real Estate (01997) saw declines of 3.52% and 3.57%, respectively, negatively impacting the index [2] Sector Highlights Technology Sector - Major tech stocks mostly rose, with Kuaishou increasing by 11% and Alibaba by over 2% [3] - The brain-computer interface concept gained traction following Elon Musk's announcement of large-scale production plans for Neuralink in 2026 [4] Real Estate Sector - The real estate sector showed strong performance, with Greentown China (03900) rising 6.56% and Shimao Group (00813) up 5.76% [4] - An article in "Qiushi" magazine emphasized the importance of stabilizing market expectations in the real estate sector, suggesting proactive measures to shorten adjustment periods [4] Pharmaceutical Sector - Pharmaceutical stocks performed robustly, with Zhaoyan New Drug (06127) up 13.73% and Yimeng Biotech (09606) up 11.81% [5] - The National Medical Products Administration reported a record number of approved innovative drugs in 2025, significantly exceeding previous years [5] Insurance Sector - Insurance stocks collectively rose, with New China Life (01336) increasing by 5.34% and China Life (02628) by 3.4% [6] - The insurance industry reported a 7.6% year-on-year growth in premium income for the first 11 months of 2025 [6] Automotive Sector - Automotive stocks faced declines, with Great Wall Motors (02333) down 6.15% and XPeng Motors (09868) down 4.6% [6] - The 2026 vehicle trade-in subsidy policy will continue, with adjustments to subsidy amounts based on vehicle pricing [7] Oil Sector - Oil stocks were generally weak, with China National Petroleum (00857) down 3.52% [7] - The geopolitical situation in Venezuela may impact oil prices, with potential increases in production posing risks for future pricing [7] Notable Stock Movements - Woan Robotics (06600) reached a new high, closing up 19.57% at HKD 110, with plans to launch a humanoid home robot in January 2026 [8] - Black Sesame Technologies (02533) rose 11.21% after announcing its high-performance smart driving chip received approval for global sales [9]

Group 1 - The cell immunotherapy concept increased by 4.73%, ranking 7th among concept sectors, with 56 stocks rising, including Guanhao Biological reaching a 20% limit up [1] - Notable gainers in the sector include International Medicine, Saily Medical, and Zhaoyan New Drug, all hitting the limit up, while stocks like Saifutian and *ST Biology experienced declines [1][2] - The cell immunotherapy sector saw a net inflow of 1.058 billion yuan, with 38 stocks receiving net inflows, and Zhaoyan New Drug leading with a net inflow of 232 million yuan [2][3] Group 2 - The top stocks by net inflow ratio include Saily Medical at 57.96%, International Medicine at 41.60%, and Zhaoyan New Drug at 22.45% [3] - The trading performance of key stocks shows Zhaoyan New Drug and Saily Medical both achieving over 10% gains, while Guanhao Biological reached a 20% increase [3][4] - Other notable performers include Bibeite and Yuekang Pharmaceutical, with increases of 11.84% and 10.13% respectively [1][5]

1. 脑机接口概念爆发。截至收盘，南京熊猫电子股份(00553)涨39.75%，报6.75港元；微创脑科学 (02172)涨19.73%，报13.53港元；脑动极光-B(06681)涨15.74%，报7.87港元；心玮医疗-B(06609)涨 9.62%，报59.85港元。 据报道，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。开源证券在最新研报中强调，当前脑机接口行业正处于技术突破、政策扶持与机器人 生态协同三大驱动力共振的高增长蓄势阶段。据Precedence Research预测，全球脑机接口市场规模有望 在2034年达到124亿美元，2025至2034年复合年增长率达17%。 2. 内房股表现亮眼。截至收盘，绿城中国(03900)涨6.56%，报8.93港元；世茂集团(00813)涨5.76%，报 0.202港元；华润置地(01109)涨5.05%，报29.12港元；龙湖集团(00960)涨4.81%，报9.16港元。 港股三大指数今早冲高回落，盘中均一度录得下跌，恒指及恒科指数尾盘翻红。截止收盘，恒生指数涨 0.03%或8.77点， ...

截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 FF301 由於北京昭衍新藥研究中心股份有限公司(「本公司」)是於中華人民共和國註冊成立，因此" 法定股本"之概念不適用於本公司。第 I 部分所載資料是指本公司的"已發行股本"。 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 ...

Market Overview - The A-share market opened positively in 2026, with the Shanghai Composite Index rising for 12 consecutive days, closing above 4000 points at 4023.42, up 1.38% [1][2] - The Shenzhen Component Index increased by 2.24% to 13828.63, while the ChiNext Index rose by 2.85% to 3294.55 [1][2] - Total market turnover reached 2.57 trillion yuan, an increase of 501.5 billion yuan from the previous trading day, with nearly 4200 stocks rising [1] Sector Performance Brain-Computer Interface Sector - The brain-computer interface sector experienced a surge, with over 30 stocks hitting the daily limit, driven by Elon Musk's announcement of large-scale production of brain-computer interface devices by Neuralink in 2026 [4] - Notable stocks include: - BeiYikang: +29.98% [5] - DaoShi Technology: +20.01% [5] - Sanbo Brain Science: +20.01% [5] - MeiHao Medical: +20.00% [5] Insurance Sector - The insurance sector saw significant gains, with New China Life Insurance rising over 8% and China Pacific Insurance increasing by 7.52% [7] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [6] Storage Chip Sector - The storage chip sector also performed well, with stocks like Yunhan Chip City and Puran Shares hitting the daily limit, and Zhongwei Company rising over 14% [8] Gaming Sector - The gaming sector rebounded, with stocks such as Tom Cat rising over 16% and Sanqi Interactive Entertainment hitting the daily limit [9] Precious Metals Sector - The precious metals sector saw gains, with Hunan Silver hitting the daily limit and Western Gold rising over 6% [10] Innovative Drug Sector - The innovative drug sector experienced a broad increase, with stocks like GuanHao Biological hitting the daily limit [11] - In 2025, 76 innovative drugs were approved for market, setting a historical record, with total licensing transactions exceeding 130 billion USD [11] Hainan Free Trade Zone Sector - The Hainan Free Trade Zone sector faced a collective adjustment, with Hainan Development hitting the daily limit down and Haiqi Group falling over 8% [13] Transportation and Tourism Sector - The transportation and tourism sectors showed weakness, with Hainan Airport down 4.69% and various tourism stocks declining [15][14] Market Outlook - Looking ahead, the market may continue to exhibit structural trends, supported by positive investor sentiment from the strengthening of the Hong Kong market and the renminbi exchange rate [18] - The upcoming Spring Festival may trigger an early market rally, with a focus on technology leaders and cyclical sectors benefiting from price recovery expectations [18]

Group 1 - The core viewpoint of the articles highlights the significant growth in China's innovative drug sector, with 76 innovative drugs approved for market by 2025, surpassing 48 in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, representing a year-on-year increase of over 150%, with more than 150 transactions, also a historical record [1] - The cash flow from business development (BD) and the IPO boom are providing substantial funding for research and development in the pharmaceutical industry, indicating a transition into an "era of innovative drugs" starting in 2026 [1] Group 2 - The Hong Kong innovative drug ETF (513120) saw a strong increase of 4.49% as of January 5, 2026, with a nearly 6% rise during the trading session, and a cumulative increase of 69.12% over the past year [2] - The latest scale of the Hong Kong innovative drug ETF reached 23.403 billion yuan, with a total inflow of 121 million yuan over the past eight trading days [2] - The ETF supports T+0 trading, allowing investors to conduct multiple transactions within a trading day, enhancing liquidity and capital efficiency [2]

Group 1 - The core viewpoint of the news highlights the significant surge in the brain-computer interface (BCI) sector, driven by advancements and investments, particularly from Elon Musk's Neuralink, which plans to start large-scale production of BCI devices by 2026 [1] - The China Securities Regulatory Commission has included BCI in future industries, with a two-step development goal set for the next five years, indicating strong governmental support for the sector [1] - The medical device ETF (159883) has shown a notable increase of 5.54%, with a net subscription exceeding 181 million units, reflecting investor confidence in the BCI and medical technology sectors [1] Group 2 - The application of BCI technology in medical fields, particularly for mental health, rehabilitation, and health management, is expected to accelerate due to supportive policies [2] - The medical device ETF (159883) tracks the medical device sector and has a strong technological focus, with over 80% of its components coming from the Sci-Tech Innovation Board and the Growth Enterprise Market [2] - The Hong Kong medical ETF (159366) has also performed well, rising 5.34%, with significant gains in individual stocks related to brain science and medical technology [3]

Group 1 - A-shares opened higher today, with significant gains in innovative drug and brain-computer interface stocks, including Zhaoyan New Drug and BeiGene, which rose over 10% [1] - The innovative drug ETF Tianhong (517380) tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index surged over 4.8%, outperforming the Hong Kong Stock Connect Innovative Drug Index [1] - The biopharmaceutical ETF (159859) tracking the Guozhen Biopharmaceutical Index increased by over 3%, with a total scale exceeding 3.3 billion yuan and a net inflow of over 600 million yuan since September last year [1] Group 2 - The National Medical Products Administration has organized the formulation of the "Priority Approval High-end Medical Device Catalog (2025 Edition)," including medical electronic accelerators and implantable brain-computer interface medical devices [1] - Elon Musk announced that his brain-computer interface company, Neuralink, will begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [1] - Analysts indicate that including implantable brain-computer interface medical devices in the priority approval category highlights policy support for related technological developments, with a broad potential market space and accelerated commercialization processes expected [1] Group 3 - McKinsey estimates that the global market size for brain-computer interface medical applications could reach $40 billion by 2030 and $145 billion by 2040, indicating significant application potential in the medical field [2] - Investors interested in the innovative drug sector can consider the innovative drug ETF Tianhong (517380) for easy access, while off-market investors may focus on linked funds [2] - The emphasis is on CXO and innovative drug mainline trends, with a recommendation to focus on the biopharmaceutical ETF (159859) that targets 30 industry leaders for higher sharpness and elasticity [2]